GlassScriptPhysician profile
Benjamin Taylor Colston
NPI 1194234468
$14,220.47
in general payments reported to CMS, 2019-2025
50 companies · $18.60 in 2025
The $18.60 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,377 · 2022: $2,678 · 2023: $3,962 · 2024: $5,184 · 2025: $18.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,589 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,588.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,294.74 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $749.56 | 2021-2024 | Austedo Xr, Ajovy, Austedo |
| Biogen, INC. | $621.37 | 2021-2024 | Vumerity |
| Genzyme Corporation | $600.80 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $580.55 | 2021-2024 | Ingrezza, Ongentys |
| Pfizer INC. | $501.27 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $466.93 | 2022-2024 | |
| Celgene Corporation | $430.95 | 2022-2024 | Zeposia |
| Ucb, INC. | $401.56 | 2021-2024 | Rystiggo, Fintepla, Briviact |
| Supernus Pharmaceuticals, INC. | $366.88 | 2021-2025 | Qelbree |
| Mdd US Operations, LLC | $350.03 | 2022-2024 | Gocovri |
| Lilly USA, LLC | $326.32 | 2023-2024 | Amyvid, Emgality, Reyvow |
| Alexion Pharmaceuticals, INC. | $324.51 | 2021-2024 | Ultomiris, Soliris |
| Emd Serono, INC. | $277.43 | 2022-2024 | Mavenclad |
| Acadia Pharmaceuticals INC | $270.83 | 2023-2024 | Nuplazid |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $248.30 | 2022-2024 | Rexulti, Nuedexta |
| Argenx US, INC. | $246.83 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $227.84 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $164.53 | 2022 | |
| Horizon Therapeutics Plc | $153.75 | 2021-2023 | Uplizna |
| Jazz Pharmaceuticals INC. | $140.43 | 2021-2023 | Epidiolex, Xywav |
| Avanir Pharmaceuticals, INC. | $123.44 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $122.29 | 2021-2023 | |
| Adamas Pharmaceuticals, INC. | $121.08 | 2021 | |
| Tg Therapeutics, INC. | $99.74 | 2023 | |
| Amgen INC. | $83.58 | 2022-2024 | Uplizna |
| Ani Pharmaceuticals, INC. | $72.89 | 2023-2024 | Purified Cortrophin Gel |
| Sk Life Science, INC. | $72.47 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $68.29 | 2022-2023 | Zeposia |
| Merz Pharmaceuticals, LLC | $68.12 | 2022-2023 | Xeomin |
| Arbor Pharmaceuticals, INC. | $57.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.36 | 2023-2024 | Hyqvia |
| Amneal Pharmaceuticals LLC | $51.18 | 2021-2023 | Rytary |
| Avion Pharmaceuticals | $48.09 | 2022 | |
| Genentech USA, INC. | $45.94 | 2023 | Ocrevus |
| Cala Health, INC. | $41.43 | 2022 | |
| Mallinckrodt Hospital Products INC. | $40.61 | 2023-2024 | Acthar |
| Livanova USA, INC. | $34.45 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $33.23 | 2023-2024 | Horizant, Horizant |
| Scilex Pharmaceuticals INC. | $31.11 | 2023 | Ztlido |
| Harmony Biosciences LLC | $30.86 | 2024 | |
| Acorda Therapeutics, INC | $29.16 | 2023 | Inbrija |
| Alfasigma USA, INC. | $24.02 | 2022 | |
| Neurelis, INC. | $20.97 | 2024 | Valtoco |
| Sandoz INC. | $20.20 | 2023 | |
| Nevro Corp. | $19.58 | 2023 | Senza |
| Idorsia Pharmaceuticals US INC | $16.61 | 2023 | Quviviq |
| Lundbeck LLC | $16.08 | 2024 | Rexulti |
| Kyowa Kirin, INC. | $14.86 | 2021 | |
| Sumitomo Pharma America, INC. | $14.54 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Colston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.